KR20120104177A - 암을 치료하기 위한 톨 유사 수용체 및 효능제의 용도 - Google Patents

암을 치료하기 위한 톨 유사 수용체 및 효능제의 용도 Download PDF

Info

Publication number
KR20120104177A
KR20120104177A KR1020127008759A KR20127008759A KR20120104177A KR 20120104177 A KR20120104177 A KR 20120104177A KR 1020127008759 A KR1020127008759 A KR 1020127008759A KR 20127008759 A KR20127008759 A KR 20127008759A KR 20120104177 A KR20120104177 A KR 20120104177A
Authority
KR
South Korea
Prior art keywords
hours
vector
mammal
flagellin
toll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127008759A
Other languages
English (en)
Korean (ko)
Inventor
안드레이 브이. 구드코프
Original Assignee
파나셀라 랩스, 아이엔씨.
로스웰 파크 캔서 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파나셀라 랩스, 아이엔씨., 로스웰 파크 캔서 인스티튜트 filed Critical 파나셀라 랩스, 아이엔씨.
Publication of KR20120104177A publication Critical patent/KR20120104177A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020127008759A 2009-10-06 2010-10-06 암을 치료하기 위한 톨 유사 수용체 및 효능제의 용도 Ceased KR20120104177A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24925309P 2009-10-06 2009-10-06
US61/249,253 2009-10-06
US24959609P 2009-10-07 2009-10-07
US61/249,596 2009-10-07

Publications (1)

Publication Number Publication Date
KR20120104177A true KR20120104177A (ko) 2012-09-20

Family

ID=43857117

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127008759A Ceased KR20120104177A (ko) 2009-10-06 2010-10-06 암을 치료하기 위한 톨 유사 수용체 및 효능제의 용도

Country Status (16)

Country Link
US (1) US9205095B2 (enExample)
EP (1) EP2486134B1 (enExample)
JP (2) JP5796014B2 (enExample)
KR (1) KR20120104177A (enExample)
CN (1) CN104136614B (enExample)
AP (1) AP2012006253A0 (enExample)
AU (1) AU2010303464B2 (enExample)
BR (1) BR112012011331B8 (enExample)
CA (1) CA2777198C (enExample)
EA (1) EA021842B1 (enExample)
ES (1) ES2457518T3 (enExample)
IL (1) IL219060A (enExample)
MX (1) MX2012004095A (enExample)
MY (1) MY163110A (enExample)
WO (1) WO2011044246A1 (enExample)
ZA (1) ZA201202500B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101634380B1 (ko) 2015-06-23 2016-06-28 한국생산기술연구원 Tlr5 아고니스트 단백질의 생산방법
KR20210098544A (ko) * 2016-12-28 2021-08-10 에이에스엠엘 네델란즈 비.브이. 메트롤로지 이미지와 디자인 사이의 시뮬레이션-지원 정렬
WO2021246666A1 (ko) * 2020-06-04 2021-12-09 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 항암제 조성물

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5285278B2 (ja) 2004-12-22 2013-09-11 クリーブランド クリニック ファウンデイション フラゲリン関連ポリペプチドおよびその使用
JP5577337B2 (ja) 2008-08-01 2014-08-20 クリーブランド バイオラブス， インコーポレイテッド 再灌流傷害を治療するための方法
EP2663367A4 (en) 2011-01-10 2014-08-06 Cleveland Biolabs Inc USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
WO2014098649A1 (en) * 2012-12-18 2014-06-26 Obschestvo S Ogranichennoy Otvetstvennostyu "Panacela Labs" Compositions and methods using toll-like receptor 5 and toll-like receptor agonist
RU2682762C2 (ru) * 2013-11-27 2019-03-21 Общество С Ограниченной Ответственностью "Панацела Лабс" Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака
EP3174893B1 (en) * 2014-07-30 2020-05-06 Genome Protection, Inc. Flagellin compositions and uses
WO2016056596A1 (ja) 2014-10-07 2016-04-14 日本電気株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
WO2016109002A2 (en) 2014-10-16 2016-07-07 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
US10526388B2 (en) 2015-03-09 2020-01-07 Cytlimic Inc. Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells
AU2016244570B2 (en) 2015-04-07 2020-08-27 Nec Corporation Medicine
CN105801709B (zh) * 2016-04-29 2019-10-08 北京纽莱福生物科技有限公司 CBLB502-Fc融合蛋白及其制备方法
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
CN108853144A (zh) * 2017-05-16 2018-11-23 科济生物医药（上海）有限公司 Toll样受体激动剂与免疫效应细胞的联用
US10717767B2 (en) 2017-07-20 2020-07-21 Spogen Biotech, Inc. Bioactive polypeptides for improvements in plant protection, growth and productivity
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
US12440536B2 (en) 2018-05-18 2025-10-14 The University Of Hong Kong Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof
WO2020041720A1 (en) 2018-08-24 2020-02-27 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
JP2022519275A (ja) 2019-02-04 2022-03-22 コディアック バイオサイエンシーズ， インコーポレイテッド エクソソーム操作のための膜タンパク質足場
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
EP3941607A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
CN114727947A (zh) 2019-09-25 2022-07-08 科迪亚克生物科学公司 细胞外囊泡组合物
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022066898A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2025196053A1 (en) * 2024-03-18 2025-09-25 Istituto Europeo Di Oncologia S.R.L. Flagellin-related peptides and uses thereof
EP4620482A1 (en) * 2024-03-18 2025-09-24 Istituto Europeo di Oncologia S.r.l. Flagellin-related peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703146B2 (en) * 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US8580321B2 (en) * 2003-12-02 2013-11-12 The Cleveland Clinic Foundation Method for reducing the effects of chemotherapy using flagellin related polypeptides
JP5285278B2 (ja) 2004-12-22 2013-09-11 クリーブランド クリニック ファウンデイション フラゲリン関連ポリペプチドおよびその使用
AR052195A1 (es) * 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101634380B1 (ko) 2015-06-23 2016-06-28 한국생산기술연구원 Tlr5 아고니스트 단백질의 생산방법
US10711049B2 (en) 2015-06-23 2020-07-14 Korea Institute Of Industrial Technology Method for producing TLR5 agonist protein
KR20210098544A (ko) * 2016-12-28 2021-08-10 에이에스엠엘 네델란즈 비.브이. 메트롤로지 이미지와 디자인 사이의 시뮬레이션-지원 정렬
WO2021246666A1 (ko) * 2020-06-04 2021-12-09 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 항암제 조성물

Also Published As

Publication number Publication date
CN104136614B (zh) 2018-04-06
JP2013506437A (ja) 2013-02-28
ZA201202500B (en) 2013-06-26
EP2486134A1 (en) 2012-08-15
AU2010303464B2 (en) 2014-05-01
EA021842B1 (ru) 2015-09-30
BR112012011331B1 (pt) 2021-03-02
CA2777198A1 (en) 2011-04-14
IL219060A (en) 2017-02-28
US20120208871A1 (en) 2012-08-16
MX2012004095A (es) 2012-09-12
BR112012011331B8 (pt) 2021-05-25
US9205095B2 (en) 2015-12-08
IL219060A0 (en) 2012-06-28
AP2012006253A0 (en) 2012-06-30
EA201290140A1 (ru) 2012-11-30
MY163110A (en) 2017-08-15
EP2486134B1 (en) 2014-01-08
EP2486134A4 (en) 2013-02-13
ES2457518T3 (es) 2014-04-28
CN104136614A (zh) 2014-11-05
AU2010303464A1 (en) 2012-04-12
BR112012011331A2 (pt) 2015-09-15
WO2011044246A1 (en) 2011-04-14
JP2015165821A (ja) 2015-09-24
CA2777198C (en) 2018-07-24
HK1199058A1 (en) 2015-06-19
JP5796014B2 (ja) 2015-10-21

Similar Documents

Publication Publication Date Title
JP5796014B2 (ja) がんを処置するためのトール様受容体およびトール様受容体アゴニストの使用
US10265390B2 (en) Use of toll-like receptor agonist for treating cancer
US8609625B2 (en) Method for enhancing immune response in the treatment of infectious and malignant diseases
TWI774651B (zh) 包含融合有免疫球蛋白Ｆｃ之介白素-７的用於預防或治療人類乳頭狀瘤病毒相關疾病的藥學組成物
EP0893507A1 (en) Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
RU2682762C2 (ru) Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака
JP7649923B2 (ja) ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用
WO2022216949A1 (en) Fusion protein for antigen presentation
HK1199058B (en) Use of toll-like receptor and agonist for treating cancer
KR20260008678A (ko) 아포지질단백질 및 Fc 부위 결합 펩타이드를 포함하는 융합 단백질 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120404

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20120718

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151006

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170317

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171221

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170317

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I